All In Biotech

Drug Trial Radar · NCT07456059

A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults

A Phase 1, Single-center, Open-label, Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Dose and Multiple Doses of EDG-7500 in Healthy Adult Caucasian and Japanese Participants

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Mar 10, 2026

Primary completion

Jun 1, 2026

Study completion Jun 1, 2026

Sponsor

Lead sponsor
Edgewise Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after single and multiple doses in Japanese and Caucasian adults. The safety of EDG-7500 in these adult participants will also be evaluated in this study.

Conditions

  • Healthy Adult Participants

Interventions

  • EDG-7500Drug

    Solid oral formulation of EDG-7500

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-lastTime frame: Day 1 to Day 13
  2. AUC0-infTime frame: Day 1 to Day 13
  3. AUCtauTime frame: Day 1 to Day 13
  4. CmaxTime frame: Day 1 to Day 13
  5. Cmax,ssTime frame: Day 1 to Day 13

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.